

5 October 2021

CLEANSING NOTICE

Notice under section 708A(5)(e) of the Corporations Act 2001

This notice is given by IMEXHS Limited (ABN 60 096 687 839) (“Company”) under section 708A(5)(e) of the Corporations Act 2001 (“Corporations Act”).

On 26 July 2021, IMEXHS announced it had entered into an agreement for the acquisition of Colombia-based radiology services provider RIMAB SAS (RIMAB) (Acquisition).

The Company issued 2,332,172 fully paid ordinary shares (“Shares”) on 5 October 2021, as part consideration for the Acquisition.

The Company advises that:

- (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Act;
- (b) this notice is being given under section 708A(5)(e) of the Act;
- (c) as a disclosing entity, the Company is subject to regular reporting and disclosure obligations;
- (d) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the Act, as they apply to the Company; and
 - (ii) section 674 of the Act; and
- (e) as at the date of this notice, there is no information that is “excluded information” within the meanings of sections 708A(7) and 708A(8) of the Act except as set out below.

The Company as a matter of business as usual has a range of prospective contracts at various stages of process. The company has submitted a tender for a contract for the supply of software and radiology reporting which would be material to the Company’s financial performance if successful. The Company is expecting to be notified of the outcome of the tender proposal in October 2021.

Authorised for release by the board of IMEXHS Limited

-ENDS-



For more information, please contact:

Media and Investor Relations

Vanessa Beresford, Citadel-MAGNUS

E: vberesford@citadelmagnus.com

T: +61 451 422 892

Business Inquiries

Reena Minhas, CFO & Company Secretary

E: enquiries@imexhs.com.au

T: +61 438 481 139

Forward-looking statements

This ASX release includes certain forward-looking statements that are based on information and assumptions known to date and are subject to various risks and uncertainties. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of IMEXHS. These factors may cause actual results to differ materially from those expressed in the statements contained in this announcement.

About IMEXHS

IMEXHS Limited (ASX: IME) is a leading imaging Software-as-a-Service (SaaS) and ancillary solutions provider with 310 sites and distributors in 15 countries. Founded in 2012, IMEXHS is known for its innovation in the imaging services market, offering flexible and scalable imaging solutions via its AQUILA branded suite of solutions for next generation Picture Archiving and Communications System (PACS) and integrated medical imaging systems (including a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS)). The AQUILA™ system is completely cloud-based, vendor neutral and zero footprint with no need for installed software. The IMEXHS products are designed to increase productivity and save money for end users, with a scalable platform that is configured for the future and enhances patient outcomes. For more information, visit www.imexhs.com